This $563,500 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports the development and characterization of a novel nanobody-based complement inhibitor for treating complement-mediated hematologic diseases. The research aims to develop additional complement inhibitor candidates (R61 phase) and evaluate the lead compound's efficacy and pharmacokinetics in preclinical models of paroxysmal nocturnal...
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), has awarded Antlia Bioscience, Inc. a Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) totaling $999,998.00 to develop a novel long-acting conjugate of the vasodilative hormone, human brain natriuretic peptide (hBNP), for the treatment of resistant hypertension. The funding will support bulk manufacturing of the clinical-grade PAS(400)-hBNP compound, pharmacokinetic and...
The National Heart, Lung, and Blood Institute (NHLBI) awarded Novomedix LLC a $306,872 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837). The goal of this 17-month grant, with an end date of February 28, 2025, is to develop and commercialize a novel, safer, and more effective therapy for the treatment of idiopathic pulmonary fibrosis (IPF) and other progressive pulmonary fibrotic diseases. Novomedix has developed a series of small molecule compounds that inhibit...
The National Heart, Lung, and Blood Institute (NHLBI) awarded Covenant Therapeutics LLC a $249,965 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) on September 10, 2023. The purpose of this grant is to further develop a novel therapeutic approach involving small peptide erythropoietin (EPO) analogs as an alternative to recombinant human EPO for the treatment of anemias, particularly those secondary to renal disease and malignancy. The key objectives are to optimize the lead...
This $299,790 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development of novel allosteric modulators of the thrombin receptor, protease-activated receptor 1 (PAR1), called Parmodulins, for the treatment of sickle cell disease (SCD). The project aims to identify optimized Parmodulins with improved potency and oral activity, and confirm their efficacy in mouse models of SCD, including...
This Project Grant award, valued at $1,909,362, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The goal of the funded project is to perform a side-by-side evaluation of the top three most promising NOX4 inhibitor drug candidates for the treatment of pulmonary fibrosis, with a focus on validating selectivity, assessing mode of action, and determining the therapeutic index and maximum tolerated...
This federal Project Grant award, valued at $1,583,398.00 and granted by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), supports the development of first-in-class, best-in-class RNA-based gene therapeutics to improve the standard of care for a range of blood and vascular diseases. The key products and services to be delivered through this funding include: Selection and characterization of highly effective, naked short interfering RNA...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837) aims to advance the development of a novel therapeutic for the treatment of Group 3 pulmonary hypertension (PH) due to interstitial lung disease (PH-ILD). The $4,950,681 award to Halo Biosciences Inc. will fund three key efforts: 1) developing an orally disintegrating tablet formulation of the hyaluronan (HA) inhibitor...
This $306,656 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development of a novel biotechnological approach to synthesize heparin-like anticoagulant drugs using engineered microbial cellular factories. The funded project, led by awardee Bioparin, LLC, aims to expeditiously produce unfractionated heparin (UFH) and low molecular weight heparins (LMWHs) as alternatives to the current...
The National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded a $548,708 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Oncoarendi Therapeutics LLC. The grant's objective is to develop a novel, disease-modifying oral medication for idiopathic pulmonary fibrosis (IPF) that targets the myocardin-related transcription factor (MRTF) pathway. The key goals of this Phase I project are to optimize a lead compound...
Novelmed Therapeutics, Inc. was awarded a $1,599,495 Project Grant from the National Heart, Lung and Blood Institute of the Department of Health and Human Services. The grant falls under the Cardiovascular Diseases Research program (CFDA 93.837), which supports heart and vascular research.
Novelmed will use the funding to develop a novel disease-modifying treatment for paroxysmal nocturnal hemoglobinuria (PNH). The company's lead drug candidate selectively inhibits the alternative pathway of complement, preventing extravascular hemolysis and anemia without blocking the classical pathway required for host defense. If successful, this alternative pathway-specific inhibitor will replace Soliris as a superior therapy for PNH by addressing complications associated with Soliris treatment, such as uncontrolled hemolysis and vulnerability to secondary infections. Novelmed will conduct a Phase II clinical trial to evaluate the drug's effects on PNH patients compared to standard Soliris treatment.